Browse recruiting and upcoming clinical trials for hemophagocytic lymphohistiocytosis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIPeople aged 14–70 with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis (HLH) who meet the study's medical criteria.
What is being studied AITests Golidocitinib monotherapy in people with hemophagocytic lymphohistiocytosis
Who can join AIPeople aged 14–80 with hemophagocytic lymphohistiocytosis (HLH) who have definite or suspected B‑cell lymphoma or increased CD20+ B cells on bone marrow testing.
What is being studied AITests zanubrutinib plus rituximab (with prednisone, ruxolitinib ± emapalumab) for secondary HLH in B‑cell lymphoma
Who can join AIAdults (18+) with active, newly diagnosed hemophagocytic lymphohistiocytosis (HLH) who meet HLH‑2004 criteria or have familial/primary HLH.
What is being studied AITests ruxolitinib plus a de-intensified HLH-94 regimen for newly diagnosed adult HLH.
Who can join AIChildren and young people (0–22 years) with primary haemophagocytic lymphohistiocytosis (HLH) confirmed by genetics or HLH diagnostic criteria, who have not had specific HLH treatment.
What is being studied AITests ruxolitinib plus steroids as first-line treatment for primary HLH.
Who can join AIPeople aged 2 months–55 years with non‑malignant disorders treatable by hematopoietic stem‑cell transplant (examples: immune, metabolic, hereditary anemias, inflammatory conditions).
What is being studied AITests reduced-intensity conditioning before stem cell transplant vs standard myeloablative conditioning.
Who can join AIChildren (<18) undergoing first allogeneic HSCT for EBV-positive T/NK‑cell lymphoproliferative disease or refractory/relapsed EBV‑related HLH.
What is being studied AITests whether letermovir given after transplant affects post-transplant viral infections and complications.
Who can join AIAdults (18–120 years) with secondary hemophagocytic lymphohistiocytosis (sHLH), macrophage activation syndrome, or related hyperinflammatory syndromes.
What is being studied AICollects clinical data and blood samples for immune, biomarker, and gene-expression studies in sHLH.
Who can join AIPeople aged 2 months–60 years with non-malignant disorders (e.g., primary immunodeficiency, bone marrow failure, inherited metabolic disorders, hereditary anemias, inflammatory conditions) undergoing UCB, bone marrow, or peripheral blood stem cell transplant with a reduced-intensity conditioning regimen.
What is being studied AICollects clinical outcomes after alemtuzumab-based reduced-intensity conditioning stem cell transplants.
Who can join AICritically ill patients (e.g., sepsis, ARDS, trauma, liver failure, burns, CAR‑T CRS) who are planned to receive or are receiving CytoSorb® therapy.
What is being studied AICollects clinical data on real-world use of the CytoSorb hemoperfusion device.
Trials that may include hemophagocytic lymphohistiocytosis (3)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIPeople with relapsed or refractory rheumatic and immunologic disease–associated haemophagocytic lymphohistiocytosis (also called macrophage activation syndrome).
What is being studied AITests plonmarlimab's efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics.